On April 2, 2021, Air Canada announced that it had abandoned its plan to acquire Transat, a competing operator in the market for air transport services between Canada and the EEA. The deal was notified on April 16, 2020 and after one year of discussions and repeated suspensions of the investigation by the Commission, Air Canada decided to abandon the €127 million deal.
The Conseil d’Etat Holds That It Is Not Competent To Hear an Objection Against an FCA’s Referral of a Merger to the Commission
On April 1, 2021 the Conseil d’Etat ruled that it lacks jurisdiction to review a French Competition Authority (“FCA”) decision referring a contemplated merger to the European Commission (“Commission”) under Article 22 of the EU Merger Regulation (“EUMR”).[1]
The Commission Withdraws Its 2019 Decision Imposing Binding Commitments in the PayTV Investigation
On March 31, 2021, the Commission withdrew its decision which made binding—under Article 9 of Regulation No 1/2003—commitments offered by NBCUniversal, Sony, TWDC, Twentieth Century Fox, Warner Bros and Sky in the cross-border access to pay-TV antitrust proceedings.[1] The withdrawal follows the annulment by the Court of Justice of the Commission’s commitments decision against Paramount and its parent company Viacom[2] (the “Paramount Commitments Decision”), who had offered essentially identical commitments to those offered by the parties in the present case.
Transforming European Merger Control: The Commission Specifies When It Will Seek To Review Mergers That Are Not Subject to Any Filing Requirements
Essential Facilities Doctrine: No Need To Prove Indispensability for Abuse Through Unfair Access Terms
On March 25, 2021,[1] the Court of Justice ruled that to demonstrate abuse, where a dominant undertaking has already offered access to its infrastructure but on unfair terms, it is not necessary to show that access to the infrastructure is indispensable within the meaning of the Court of Justice’s Bronner essential facilities doctrine.
The Court of Justice’s Lundbeck Ruling Finds Nothing New Under the Sun for By-object Restrictions
On March 25, 2021, the Court of Justice dismissed the appeals of H. Lundbeck A/S and Lundbeck Limited (“Lundbeck”), as well as of certain generic drugmakers (“generics”),[1] against the General Court judgments upholding the first-ever so-called pay-for-delay Commission decision.
Pometon v. Commission: The Court of Justice Sheds Light on the Principle of Equal Treatment and the Presumption of Innocence in Hybrid Cartels Settlements
On March 18, 2021, the Court of Justice ruled on Pometon SpA (“Pometon”)’s appeal against the General Court’s judgment in the steel abrasives[1] hybrid cartel settlement case. The Court of Justice ruled that the General Court had breached the principle of equal treatment when recalculating the fine imposed on Pometon by the Commission in 2016, the only non-settling party in this case. The Court of Justice therefore further reduced Pometon’s fine to €2.6 million, imposing an approximate 60% discount on the original fine calculated by the Commission.[2]
Commission Says PPC Might Have Engaged in Predatory Bidding and Hindered Greece’s Efforts To Go Green
On March 16, 2021, the Commission announced the opening of a formal investigation into Public Power Corporation (“PPC”), the largest wholesale and retail electricity supplier in Greece, and majority-owned by the Greek State, for allegedly abusing its dominance in the Greek wholesale electricity sector through predatory pricing strategies arising from its bidding behavior.[1]
The Council of State Turns to the ECJ Again in the Roche-Novartis Case
On March 15, 2021, the Council of State delivered a non-final judgment (the “New Judgment”) dismissing in part, on procedural grounds, the applications brought by F. Hoffmann-La Roche Ltd. and Roche S.p.A. (“Roche”), as well as Novartis Farma S.p.A. and Novartis AG (“Novartis”; jointly, the “Parties”), for the revocation of a 2019 judgment of the same court (the “2019 Judgment”).[1] By the 2019 Judgment, the Council of State upheld the ruling of the Lazio Regional Administrative Court (the “TAR Lazio”) as well as the 2014 ICA decision fining the Parties for their participation in an alleged cartel (as described below; the “ICA Decision”).[2]
Pharma Still Under the Microscope: The Commission Investigates Potentially Abusive Patent Filing Strategies
On March 4, 2021, the Commission launched a formal in-depth investigation into Teva’s patent filings conduct related to its blockbuster multiple sclerosis medicine, Copaxone.[1] This is reportedly the first time that the Commission investigates potential abuses relating to divisional patents filing strategies.[2] This announcement, together with the recent formation, on March 16, 2021, of a multilateral working group on pharmaceutical mergers with leading competition authorities, confirms the Commission’s continued interest in the pharmaceutical sector.[3]